Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclopenthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.85 |
| ▸ | CA2 | P00918 | 3/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopenthiazide SCHEMBL49142 | 0.92 | LMNA (1.00) | LMNACYP2C9ADRA2BCA2CA1 | |
| Cyclopenthiazide SCHEMBL30561852 | 0.92 | LMNA (1.00) | LMNACYP2C9ADRA2BCA2CA1 | |
| SCHEMBL29132641 | 0.91 | LMNA (0.98) | LMNACYP2C9ADRA2BCA2CA1 | |
| SCHEMBL30561876 | 0.91 | LMNA (0.98) | LMNACYP2C9ADRA2BCA2CA1 | |
| Cyclopenthiazide SCHEMBL9505656 | 0.90 | LMNA (0.96) | LMNACYP2C9ADRA2BCA2CA1 | |
| Trichlormethiazide SCHEMBL29356280 | 0.85 | LMNA (1.00) | LMNACYP2C9ADRA2BCA2CA1 | |
| Trichlormethiazide SCHEMBL25493 | 0.85 | LMNA (1.00) | LMNACYP2C9ADRA2BCA2CA1 | |
| Trichlormethiazide SCHEMBL25492 | 0.85 | LMNA (1.00) | LMNACYP2C9ADRA2BCA2CA1 | |
| Cyclopenthiazide SCHEMBL28832656 | 0.80 | LMNA (0.76) | LMNACYP2C9ADRA2BCA2CA1 | |
| Cyclopenthiazide SCHEMBL28142871 | 0.80 | LMNA (0.76) | LMNACYP2C9ADRA2BCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170166632-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | claimed |
| US-8883145-B2 | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | claimed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| EP-2699579-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |